Arkolith/Insider Trading/SDGR/Form 4

Akinsanya Karen

President of R&D, TherapeuticsSchrodinger, Inc. (SDGR) · full profile →Form 4 · filed Apr 15, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$420K
Net Open-Market Flow
-$420K
Transactions
7
5 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 14, 2025Sell(S)8K$25.11$210K24K
Apr 14, 2025Option exercise(M)13K$3.22$43K29K
Apr 14, 2025Option exercise(M)3K$2.92$10K32K
Apr 14, 2025Sell(S)5K$25.11$126K19K
Apr 14, 2025Sell(S)3K$25.00$84K16K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 14, 2025Option exercise(M)13K—$00
Apr 14, 2025Option exercise(M)3K—$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001490978-25-000036) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML